BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
加利福尼亞州聖尼韋爾，2024年11月06日(GLOBE NEWSWIRE) --biocardia公司[NASDAQ:BCDA]，一家開發心血管和肺部疾病治療的細胞和細胞衍生療法的公司，今天宣佈將於2024年9月30日至2024年9月30日結束的三個月和九個月的財務結果進行公司更新，並通過電話會議於2024年11月13日週三在美國東部時間下午4:30提供。在管理層正式講話後，將進行問答環節。
Participants can register for the conference by navigating to . Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: .
與會者可以通過轉到註冊參加會議。請注意，註冊參與者將在註冊後收到撥入號碼。對於未註冊的人來說，想通過電話收聽電話會議的感興趣方在美國境內應撥打1-833-316-0559，國際電話應該撥打1-412-317-5730。所有撥號者應在計劃開始時間前約10分鐘撥入，要求加入biocardia電話會議。電話會議也將通過實時網絡播放提供，可通過以下鏈接訪問：。
A webcast replay of the call will be available approximately one hour after the end of the call through November 27, 2024 at the following link: . A telephonic replay of the call will also be available through November 27, 2024 and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6220156.
About BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company's biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms. For more information visit .
電話會議的網絡重播將在電話會議結束後約一小時內提供，可通過以下鏈接訪問：。電話重播還將於2024年11月27日結束前提供，電話撥入1-877-344-7529(國內)，1-412-317-0088 (國際)或855-669-9658(加拿大)，使用訪問代碼6220156。
關於BioCardia
位於加利福尼亞州聖尼韋爾的biocardia 公司是全球心血管和肺部疾病治療中細胞和細胞衍生療法的領導者。CardiAMP自體和CardiALLO異體細胞療法是該公司的生物治療平台，目前有三個心臟臨床階段產品候選正在研發中。這些療法得益於其Helix生物治療遞送和Morph血管導航產品平台。更多信息請訪問。
CONTACT: MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120
聯繫方式：媒體聯繫人：
Miranda Peto，投資者關係
mpeto@biocardia.com
(650) 226-0120
投資者聯繫方式：
David McClung, 首席財務官
investors@biocardia.com
(650) 226-0120
譯文內容由第三人軟體翻譯。
